Atopic Dermatitis


Bermekimab Goes to Janssen for up to $1.35b in Deal that Could Shake up Future Hidradenitis Suppurativa & Atopic Dermatitis Market

XBiotech’s Bermekimab, a promising experimental drug generating significant interest with Hidradenitis Suppurativa patients in the TrialSite News network, has been sold to Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Bermekimab is...

Alberta, Canada Clinical Investigator Site ‘Central Alberta Research Clinic’ Leads LEO Pharma Delgocitinib Study for Atopic Dermatitis

Central Alberta Research Clinic conducts a Phase II eczema clinical trial for an investigational cream-based treatment called Delgocitinib (Leo Pharma). The Alberta clinical investigator site is one of three sites in Canada as well as nine in the U.S. conducting the...

Pin It on Pinterest